Thomas Lynch, born in 1956
Chairman since January 2007, Board member of Old Tripep in the period 2005 to 2006.
Other assignments: Thomas Lynch is a Board member of Icon Plc (a clinical research company); IDA Ireland (an Irish government agency responsible for domestic investments); Profectus Inc. (a privately-owned US biotechnology company); the Royal Opera House in London and is Chairman of the Queen's University Belfast Foundation and HRH the Prince of Wales' Foundation for Integrated Health. In the period 1993 to 2004, Thomas Lynch worked in different capacities in Europe's biggest biotechnology company, Elan Corporation Plc. In his role as Chief Financial Officer and Executive Vice President, he engineered Elan's transformation from a drug delivery corporation into a biotechnology company through a series of corporate and product acquisitions and joint ventures.
Shareholdings (directly and indirectly through a foundation): 1,074,975.